Effectiveness of pharmacological treatments for COVID-19 due to SARS-CoV-2: a systematic literature review

Effectiveness of pharmacological treatments for COVID-19 due to SARS-CoV-2: a systematic literature review

AimSince the first cases of the COVID-19 pandemic, caused by the SARS-CoV-2 virus, described in 2019, numerous drugs have been proposed for the treatment of the disease. However, studies have given contradictory or inconclusive results, making it difficult to determine which treatments are truly eff...

Full description

Saved in:

Bibliographic Details
Main Authors:	Carolina Garcia Vidal, Jonathan González, Carlos Lumbreras, Miguel Salavert, Antonio Castro, Darío Rubio-Rodríguez, Carlos Rubio-Terrés
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Pharmacology
Subjects:	COVID-19 SARS-Cov2 treatment efficacy anakinra casirivimab/imdevimab cilgavimab/tixagevimab
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1469681/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real-world effect of casirivimab and imdevimab cocktail in patients infected with SARS-CoV-2 delta and omicron variants
by: Rajas Subhash Walinjkar, et al.
Published: (2023-03-01)

Real-world clinical outcomes of tixagevimab/cilgavimab in the Omicron outbreak in China: baseline characteristics and interim analysis of the CLEAR study
by: Jianhua You, et al.
Published: (2024-10-01)

Emergency department implementation of monoclonal antibody infusion for the treatment of coronavirus disease 2019: A template for rapid deployment
by: Thomas J. Woltemate, et al.
Published: (2021-10-01)

Development of a quality by design-based ultra-performance liquid chromatography method for the simultaneous estimation of casirivimab and imdevimab with greenness metrics
by: Sravanthi Gandu, et al.
Published: (2025-06-01)

Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study
by: Jassada Buaboonnam, et al.
Published: (2024-12-01)

Dose-dependent impact of tixagevimab–cilgavimab as primary prevention against SARS-CoV-2 in immunocompromised individuals
by: Daniela Dluzynski, et al.
Published: (2025-05-01)

Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy
by: M. V. Zhuravleva, et al.
Published: (2023-07-01)

Experience with Tixagevimab and Cilgavimab (Evusheld) in 86 rheumatic patients undergoing anti-B cell therapy with rituximab
by: T. V. Beketova, et al.
Published: (2023-04-01)

Pre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results
by: T. V. Beketova, et al.
Published: (2024-11-01)

HIDDEN DANGER OF SARS-COV-2; MULTISYSTEM INFLAMMATORY SYNDROME IN ADULTS (MIS-A): FIRST CASE SERIES IN A SINGLE CENTER FROM TURKIYE
by: Aysun Benli, et al.
Published: (2022-10-01)

Main Pharmacological Strategies Against SARS-CoV-2
by: Thais Gonçalves Fontes, et al.
Published: (2020-09-01)

An overview of SARS-COV-2: Virology, Epidemiology, Pathogenesis and Treatment
by: Ramesh Bhandari, et al.
Published: (2020-06-01)

Pulling Forces Differentially Affect Refolding Pathways Due to Entangled Misfolded States in SARS-CoV-1 and SARS-CoV-2 Receptor Binding Domain
by: Pham Dang Lan, et al.
Published: (2024-10-01)

Impacto de la Pandemia por SARS-CoV2 sobre la Educación
by: Carlos Jiménez-Sánchez
Published: (2020-07-01)

SARS CoV-2 in tumor tissue in glioblastoma patients – preliminary study
by: Brzozowski Michal, et al.
Published: (2024-12-01)

Experience with the use of thixagevimab/cilgavimab for pre-exposure prophylaxis of COVID-19 in patients with HIV infection in the Omsk region
by: M. V. Balabokhina, et al.
Published: (2023-04-01)

Safety and efficacy of the Oxford-AstraZeneca vaccine against SARS-CoV-2 after 2nd and 3rd dose in adults: a cross-sectional study
by: Shahrbanoo Sedigh Sarooni, et al.
Published: (2024-12-01)

SARS-CoV-2 and Coronaviruses: Understanding Transmission, Impact, and Strategies for Prevention and Treatment
by: Seyede Nafise Tabatabaei, et al.
Published: (2025-02-01)

Interaction of SARS-CoV-2 and SARS-CoV-2 vaccines with renin angiotensin aldosterone system, clinical outcomes, and angiotensin (1-7) as a physiological treatment recommendation: hypothesis and theory article
by: Ali Rıza Aktaş
Published: (2025-07-01)

New Coronavirus COVID-19 (SARS-CoV-2)
by: O. V. Shamsheva
Published: (2020-03-01)

Genomic surveillance of SARS-CoV-2 variants using pooled WGS
by: Inho Park, et al.
Published: (2025-04-01)

Does SARS-CoV-2 Possess “Allergen-Like” Epitopes?
by: Alberto Rubio-Casillas, et al.
Published: (2025-04-01)

Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2
by: Danielle E. Anderson, et al.
Published: (2020-01-01)

Is The SARS-CoV2 Evolved in Human Being: A prospective Genetic Analysis
by: Salvatore Dimonte, et al.
Published: (2020-12-01)

SARS-CoV-2 associated encephalitis
by: Jasmina Poluga, et al.
Published: (2025-05-01)

In silico exploration of binding potentials of anti SARS-CoV-1 phytochemicals against main protease of SARS-CoV-2
by: Abdullah G. Al-Sehemi, et al.
Published: (2022-05-01)

Immunogenicity and Efficacy of Combined mRNA Vaccine Against Influenza and SARS-CoV-2 in Mice Animal Models
by: Elena P. Mazunina, et al.
Published: (2024-10-01)

The Coronavirus SARS-Cov-2: the Complexity of Infection Pathogenesis, the Search of Vaccines and Possible Future Pandemics
by: E. P. Kharchenko
Published: (2020-07-01)

A rare case of macroamylasemia in a patient with SARS-CoV-2 infection
by: Tilan Aponso, et al.
Published: (2025-02-01)

Monitoring and assessment of SARS-CoV-2 evolution
by: V. V. Miasoiedov, et al.
Published: (2022-02-01)

An algorithm for indoor SARS-CoV-2 transmission
by: Daniel Maxin, et al.
Published: (2022-10-01)

SARS-CoV-2 infection: diagnostic testing results occasionally require special attention
by: Elisabetta Riva, et al.
Published: (2020-01-01)

Pulmonary Abscess as a Complication of SARS-CoV-2 Pneumonia
by: Fatih Uzer, et al.
Published: (2022-01-01)

Driving consistency: CEPI-Centralized Laboratory Network’s conversion factor initiative for SARS-CoV-2 clinical assays used for efficacy assessment of COVID vaccines
by: Ali Azizi, et al.
Published: (2024-12-01)

The persistence of SARS-CoV-2 neutralizing antibodies after COVID-19: A one-year observation. Is a SARS-CoV-2 vaccination booster dose necessary?
by: Adam Tworek, et al.
Published: (2023-03-01)

Current opportunities to improve outcomes of COVID-19 infection prevention and course in patients with lymphoproliferative diseases (regional analysis)
by: Ch. Kh. Valiakhmetova, et al.
Published: (2023-05-01)

Guillain-Barré Syndrome Presenting with Facial Diplegia Due to SARS-CoV-2 Infection: A Case Series and Current Literature Review
by: Kadriye Guleda Keskin, et al.
Published: (2023-06-01)

A Novel Toolkit of SARS-CoV-2 Sub-Genomic Replicons for Efficient Antiviral Screening
by: Maximilian Erdmann, et al.
Published: (2025-04-01)

Vaccination against the SARS-CoV-2 in individuals with comorbidities
by: S A Berns, et al.
Published: (2025-02-01)

Mortality from Coronavirus (Covid) SARS-CoV-2 in Oncological Patients
by: Hoyos-Pulgarín, Julián Andrés, et al.
Published: (2025-04-01)